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Themyeloproliferative disorders (MPDs) are a spectrum of clonal disorders of the hematopoietic system. The
discovery of activating mutations of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythe-
mia, and primary myelofibrosis has lead to in vitro and animal model studies that promise to lead to thera-
peutic advances.The myeloproliferative disorders (MPDs)
are a spectrum of clonal disorders of the
hematopoietic system (reviewed in Levine
et al., 2007). The distinct clinical manifes-
tations are dictated by the primary cell
type affected, and thus chronic myeloid
leukemia (CML) is a proliferation of mature
granulocytes, polycythemia vera (PV) is
an expansion or red blood cells, essential
thrombocythemia (ET) results in an in-
crease of platelets, etc. (Table 1). The
natural history of MPDs is generally
chronic in nature, and patients come to
medical attention either by coincidence
(abnormal blood findings during routine
exam) or by signs and symptoms related
to the expansion of the hematopoetic
system (e.g., an enlarged spleen). Com-
mon to most MPDs is a small but finite
risk of disease evolution to an acute
leukemia, where hematopoetic develop-
ment is blocked at an early stage of differ-
entiation, leading to the accumulation of
poorly functioning myeloid blasts at an
expensive of critical depletion of normal
white blood cells and platelets, leading
to morbidity and mortality from infections
and bleeding complications. If they do not
progress to an acute leukemia, the natural
history of MPDs often results in fibrosis of
the bonemarrow, migration of hematopo-
esis to other organs (spleen and liver), and
eventual complications of this secondary
organ involvement, as well as from
decreased normal blood counts from
marrow fibrosis.
A unifying theme in the pathogenesis
of MPDs is the activation of tyrosine
kinases. The ‘‘poster child’’ is CML, where
the BCR-ABL translocation is found in all
cases; the fusion BCR-ABL activates
proliferative and antiapoptotic pathways;
and most importantly, inhibition by tyro-sine kinase inhibitors (TKIs) can markedly
reverse the natural history of the disease.
The molecular lesions responsible for PV,
ET, and myelofibrosis (MF) were unknown
until relatively recently. In 2005, a flurry
of reports found that a point mutation in
JAK2, resulting in a valine for phe-
nylalanine substitution at codon 617
(JAK2V617F), occurred at a high preva-
lence in these disorders (Baxter et al.,
2005; James et al., 2005; Kralovics et al.,
2005; Levine et al., 2005). The mutation
was found in roughly half of MF and ET
cases and nearly all PV cases. Constitu-
tive activation of JAK2 activates STAT
and MAPK proliferative signaling path-
ways, leading to transformation of hema-
topoetic progenitors. Curiously, not all
hematopoetic stem cells in cases with
the JAK2V617F harbor the mutation.
Moreover, the data suggested a differen-
tial dosage effect in the different diseases.
Whereas in most cases the JAK2V617F is
heterozygous with a normal JAK2 allele, in
many cases of PV the mutation is homo-
zygous (Kralovics et al., 2005) through
the process of acquired uniparental dis-
omy. Curiously, in vitro cultures of PV
cases will often show homozygous
JAK2V617F erythroid colonies, whereas
similar colonies from ET patients are
heterozygous for the mutation.
There has been a substantial body of
work attempting to study the effects of
the JAK2V617F in mouse models. Early
reports focused on a bone marrow trans-
plantation model, where mouse bone
marrow cells harboring exogenous JAK2-
V617F were transplanted into irradiated
mice (Wernig et al., 2006). These models
produced a syndrome of what appeared
mostly like PV, but most failed to
completely recapitulate the spectrum ofCancer Cleukocytosis, thrombocytosis, and myelo-
fibrosis found in human disease. Transge-
neic models followed, which again
produced a spectrum of MPD disorders,
with a suggestion of phenotype relating
to the JAK2V617F expression levels (Tiedt
et al., 2008). Very recently, several groups
have created knockin systems placing
a conditionally inducible JAK2V617F allele
under control of the endogenous JAK2
promoter. This allows for control of the
JAK2V617F expression in only hemato-
poetic tissues, getting one closer to repli-
cating the disease experience of the
human patient. Marty et al. found that the
heterozygous expression of JAK2V617F
produced a PV-like syndrome, not like
human where heterozygousity is more
often associated with ET (Marty et al.,
2010). However, Akada et al. demon-
strated that both heterozygous and homo-
zygous JAK2V617F caused a PV
syndrome, with a demonstration of a
dose effect, as indicated by the fact that
homozygous expressors had a greater
manifestation of elevated blood counts
and spleen size, compared to those mice
with lower levels of JAK2V617F (Akada
et al., 2010). In addition, Li et al. have
produced a very provocative study in
which a human JAK2V617F knockin was
created (Li et al., 2010). This model
produced a transplantable disease with
some features of both ET and PV. Of
interest is the finding that affected mice
had reducednumbersof primitive hemato-
poetic cells that had evidence of impaired
normal function (cell cycling, apoptosis,
and DNA damage). Moreover, competitive
marrow transplantation showed impaired
hematopoetic stem cell function.
Recently in this journal, Mullally and
colleagues make critical observationsell 18, July 13, 2010 ª2010 Elsevier Inc. 7
Table 1. Classification of MPD and Examples of Activating Mutations
Myeloproliferative Disorders Primary Cell Involved Activating Mutations
Chronic myeloid leukemia neutrophils BCR-ABL (100%)
Polycythemia vera red blood cells JAK2 (>90%)
Essential thrombocythemia platelets JAK2 (50%)
Primary myelofibrosis monocytes? JAK2 (50%)
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Previewsthat add substantially to the impressive
work summarized above (Mullally et al.,
2010). Similar to the approaches above,
the authors used a conditional JAK2-
V617F expression model to yield physio-
logical levels of the mutated allele. The
phenotype in the mice resembled much
of the cellular biology and clinical features
of human PV, and it was serially trans-
plantable with great efficiency. Separa-
tion of the bone marrow into immature
Lineage– SCA-1+ c-Kit+ (LSK) and more
mature myeloid erythroid progenitor
(MEP) and granulocytic monocytic
progenitor (GMP) subpopulations demon-
strated that the ‘‘MPD-initiating’’ JAK2-
V617F cell capable of transplantation
resided in the LSK population, but not in
the committed myeloid MEP or GMP
progenitors. Surprisingly, several studies
showed that mutant cells in the LSK
compartment were quite similar to wild-
type cells in regard to cell cycle status,
STAT signaling, and gene expression
(though JAK2V617F cells showed enrich-
ment of the erthyroid, myeloid, andmega-
karyocytic differentiation pathways).
Similar to the Li et al. paper, competitive
transplantation experiments showed that
mutant cells had at best a minor compet-
itive edge compared to wild-type, and
a small number of mutated cells nonethe-
less causes a PV phenotype. Lastly, the
authors demonstrated that the MPD-initi-
ating cell was not killed by JAK2 inhibition.
Mice treated with the inhibitor had
a dramatic decrease in spleen size and
a reduction of erthyroid precursors in the8 Cancer Cell 18, July 13, 2010 ª2010 Elsevimarrow, but LSK cells from treated mice
were able to cause the PV phenotype in
subsequently transplanted mice.
These studies in total offer an increased
understanding of the MPD that may usher
in a new era of therapy, much like what
occurred in the study of CML. Similar to
CML, these studies suggest the initiating
cell resides in the primitive compartment
but is genetically and phenotypically quite
similar to its normal complement. Like
CML, mutated cells in the stem cell
compartment appear resistant to kinase
inhibition. However, as we move toward
better therapies for MPD, these findings
have implications in the feasibility of
‘‘stem cell’’ therapy, because there may
not be a large therapeutic window to
selectively kill MPD ‘‘stem cells.’’ In addi-
tion, a limitation of murine systems is that
however eloquent, they are still only
models of human disease. For example,
human MPD may well have additional
genetic lesions contributing to initiation
and progression, and mouse models
cannot easily recapitulate this complexity.
In this regard it is interesting that several
other mutations have recently been
discovered in MPD (e.g., TET2, ASXL1,
IDH1, and IDH2); TET2 mutations have
been found in JAK2V617F-positive and
-negative clones from the same patient,
suggesting that TET2 mutations may be
a relatively early event in MPD. Moreover,
if tumor initiation and progression is influ-
enced by interactions with a host’s innate
immunological system, then disease in
the mouse model might be expected toer Inc.be very different than in humans. None-
theless, the work presented by Mullally
and others are quite significant, and
provide us with powerful tools to better
understand disease and test new agents
of therapy.REFERENCES
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